Skip to main content
PSYENCE BIOMEDICAL LTD. logo

PSYENCE BIOMEDICAL LTD. — Investor Relations & Filings

Ticker · PBM ISIN · CA74449F1181 US Manufacturing
Open in API
Filings indexed 148 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country US United States of America
Listing US PBM

About PSYENCE BIOMEDICAL LTD.

http://psyence.com

Psyence Biomedical Ltd. is a life science biotechnology company developing psychedelic and nature-centered solutions for mental health. The company specializes in creating therapies from naturally derived, non-synthetic psychedelic compounds, primarily psilocybin and ibogaine. Its core therapeutic focus is on palliative care, developing treatments for anxiety and depression in patients with life-threatening illnesses, including Adjustment Disorder in oncology patients. Additionally, Psyence Biomedical investigates the use of its botanical psilocybin for treating Alcohol Use Disorder (AUD) and other substance use disorders. The company employs a vertically integrated strategy, operating a federally licensed, ISO22000 certified facility for psilocybin cultivation and production to support its clinical trials and therapeutic development.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 90% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed with the U.S. SEC pursuant to Rule 13a-16/15d-16. It provides an amendment and restatement of the company’s equity incentive plan and furnishes the plan as an exhibit. It contains no financial statements (so it’s not an interim or annual report), no earnings or MD&A, nor any board or management change notice, proxy solicitation, or capital transaction. This is a general regulatory filing by a foreign issuer and does not fit into any more specific category, so it falls under Regulatory Filings (RNS).
2026-06-05 English
6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Psyence Biomedical Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It details an amendment to a Common Stock Purchase Agreement with White Lion Capital, including terms of an intraday purchase mechanism and related fees. The document includes an exhibit index and signatures but does not contain comprehensive financial statements or detailed financial performance data. The length is 4053 characters, which is relatively short and the document primarily serves as a regulatory announcement of a financing agreement amendment rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to amendments in financing agreements and capital structure arrangements.
2026-04-20 English
6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release dated April 17, 2026, titled 'Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine.' The document is short (1971 characters) and primarily serves to furnish a press release as an exhibit. There are no financial statements, detailed financial data, or comprehensive reports included. The document is essentially an announcement of a press release rather than a full report or detailed filing. According to the rules, such short documents that provide a press release or announcement are best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2026-04-17 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by Psyence Biomedical Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains an explanatory note about a share put option and amendment agreement, references exhibits including the agreement and a press release, and includes a signature page. The document is relatively short (2835 characters) and primarily serves as a regulatory filing to disclose a material agreement and related press release. It does not contain comprehensive financial statements or detailed financial analysis, nor is it an earnings release or annual report. It is not a certification or attestation document. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-02-13 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by Psyence Biomedical Ltd., a foreign private issuer. It reports a Settlement Agreement entered into to resolve shareholder litigation, including payment terms and share sale details. The document includes an explanatory note, exhibits (Settlement Agreement and press release), and a signature page. The content is a regulatory announcement of a legal settlement and related shareholder transaction, not a full financial report, earnings release, or management discussion. It is not an annual or interim report, nor a call transcript or capital update. The document is relatively short (2822 characters) and primarily serves as a regulatory filing to disclose material legal and shareholder information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-02-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1553 characters), and it primarily serves as a regulatory filing to report information pursuant to SEC rules. There is no indication that this is a full annual report, interim report, or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2026-01-29 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.